AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04115488 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous (IV) infusions
Description: Intravenous (IV) infusions of a dose of 300mg, every 4 weeks with a total of 12 doses
Study NCT03971968 — intervention group
Intervention type: PROCEDURE
Intervention: Skin replacement with artificial skin
Description: Integra® Dermal Regeneration Template is a bilayer membrane system for skin replacement. The dermal replacement layer is made of a porous matrix of fibers of cross-linked bovine tendon collagen and glycosaminoglycan (chondroitin-6-sulfate). The epidermal substitute layer is made of thin polysiloxane (silicone) layer to control moisture loss from the wound. The silicone outer layer temporarily closes the wound to ward off infection and control fluid and heat loss. As skin cells migrate into the matrix the collagen is slowly absorbed into the body and replaced with protein that is naturally produced by the skin. In approximately 14 to 21 days, new dermal skin is produced and the silicone layer can be removed. A thin skin graft of the person's epidermis is applied to the wound area to complete the procedure. In total, the two surgical procedures are typically completed within 30 days. A person is left with flexible growing skin and minimal damage at the skin graft donor sites.
Study NCT02662075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-cigarette/tobacco Smoking Exposure
Description: Subjects will be asked to smoke an e-cigarette containing the equivalence of nicotine in one tobacco cigarette (15 puffs) in the presence of research staff. Each puff will be timed at 4 seconds and there should be a 20-30 seconds interpuff interval as previously recommended.
Study NCT03044327 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: LPS challenge
Description: LPS inhalation and bronchial instillation
Study NCT04009122 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IGEN0206
Description: Group A
Study NCT04009122 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group B
Study NCT00598442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.025 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
Study NCT00598442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 mg/kg and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
Study NCT00598442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Participants received darbepoetin alfa by subcutaneous injection once every 2 weeks, as prescribed. The starting dose was 0.75 microgram per kilogram (mcg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
Study NCT01403636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245409
Description: Pharmaceutical form:capsule Route of administration: oral
Study NCT02662140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health Applictaion
Description: Component 1: Delivering homework via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW.~Component 2: Focuses on targeting factors putative related to poor HW implementation within the Do process
Study NCT02345499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical cystectomy with open urinary diversion
Description: Laparoscopic surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
Study NCT02345499 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open radical cystectomy with open urinary diversion
Description: Open surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
Study NCT02267031 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical ventilation
Description: Patients subjected to scheduled laparoscopic cholecystectomy were enrolled to the ongoing prospective study and randomized into four groups: 1) normoxia and normocapnia (nO2-nCO2), 2) hyperoxia and normocapnia (hO2-nCO2), 3) normoxia and hypocapnia (nO2-lCO2), and 4) hyperoxia-hypocapnia (hO2-lCO2).~Normoxia PaO2 was referred to PaO2 of 70-140 mm Hg, hyperoxia 150-300 mm Hg, normocapnia PaCO2 of 35-48 mmHg and hypocapnia PaCO2 of 25-35 mmHg.
Study NCT01979640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 39 Fr double lumen tube group
Description: additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
Study NCT01979640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 37 Fr double lumen tube group
Description: additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
Study NCT01979640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 35 Fr double lumen tube group
Description: additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
Study NCT00752895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: American ginseng
Description: Given orally
Study NCT00752895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally
Study NCT02735720 — intervention group
Intervention type: OTHER
Intervention: TEVAR
Description: Thoracic endovascular aortic repair, which includes the implantation of stent-graft in the thoracic aorta to repair the lesion. This may be done with a variety of stent-graft brands and types. The type and brand of stent-graft is left to the discretion of the care taking physician.
Study NCT02735720 — intervention group
Intervention type: OTHER
Intervention: Non-TEVAR medical treatment
Description: Any clinical management by physicians caring for these patients. This includes whatever blood pressure and heart rate medication is prescribed by the treating physician, without any surgery. The type and dosage of medication is left to the discretion of the care taking physician.
Study NCT03123627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New profilaxis
Description: Primary endpoint: incidence of CMV disease at 12 months after transplantation. Study the predictive value of the assay of CD8 + T cell immunity specific for defined CMV-patients in which they can stop prophylaxis. The definition of CMV disease was based on those recommended by the American Society of Trasnplantation for use in clinical trials (Humar A. Am J Transplant 2006; 6:262-74) criteria.
Study NCT03123627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Profilaxis recommended
Description: Secondary end points: percentage of patients developing T cell immunity in CMV-specific transplantation after receiving timoglubulina induction and valganciclovir prophylaxis. T cell development inmnunidad CD8 + CMV-specific is defined as production of γ> 0.2 interferon by CD8 + T cells stimulated by CMV-specific CMV antigens (QF reagent).
Study NCT03959306 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black Seed Oil
Description: Black seed oil soft gelatin capsule
Study NCT03959306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Diabetics
Description: standard anti-diabetic treatment prescribed for the patient
Study NCT03959306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Diabetics
Description: standard anti-diabetic treatment prescribed for the patient
Study NCT03752021 — intervention group
Intervention type: PROCEDURE
Intervention: Myometrial Sampling
Description: A myometrial sample will be obtained at the time of cesarean delivery. Sample will be obtained from the superior edge of the existing lower uterine segment incision and will be 2 inches in length and 0.5 inches in width. The uterine incision will be repaired in a standard two-layer closure. If a classical cesarean (vertical) uterine incision is deemed necessary and is performed by the surgical team, a sample of the same size will be taken parallel to the incision at the existing edge. The classical uterine incision will be closed utilizing the standard layered technique.~Placenta and gestational membrane tissue will be obtained after placental delivery. The entire placenta and attached gestational membranes will be collected if not being sent for pathologic review
Study NCT03960502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-881
Description: Single oral dose of approximately 50 mg AG-881 (free form) containing approximately 100 microcuries (μCi) of \[14C\]AG-881.
Study NCT03960502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13C315N3]AG-881
Description: Single IV microdose of approximately 100 μg.
Study NCT00750854 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NEM Formulation X
Description: see Treatment Arms
Study NCT00750854 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NEM Formulation Y
Description: see Treatment Arms
Study NCT01050738 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Position of catheter
Description: Position of catheter for administration of local anestesia.
Study NCT01852292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: Buparlisib comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
Study NCT01852292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buparlisib matching Placebo
Description: Buparlisib matching placebo comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
Study NCT01852292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is an intravenous infusion that is given once every week in 80 mg/m\^2.
Study NCT01852292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel is an intravenous infusion that is given once every week in 80 mg/m\^2.
Study NCT02586012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIII
Description: Recombinant FVIII concentrate is an FDA approved, and both efficacious and safe, therapy for the treatment and prevention of bleeding in hemophilia A. The rFVIII infusion dose will be calculated as follows: \[(weight in kg x desired FVIII increase of 100 IU/dL)/(2)\].
Study NCT00741884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Controlled Release 1.2 mg
Description: Varenicline CR tablet 1.2 mg BID for 7 weeks
Study NCT00741884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Controlled Release 1.8 mg
Description: Varenicline CR tablet 1.8 mg BID for 7 weeks
Study NCT02738554 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment cessation
Description: Cessation of nucleoside analogue therapy following European Association for the Study of the Liver guidelines
Study NCT02728089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)
Description: MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion
Study NCT00741884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Controlled Release 2.4 mg
Description: Varenicline CR tablet 2.4 mg BID for 7 weeks
Study NCT00741884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline Immediate Release 1 mg
Description: Varenicline IR tablet 1 mg BID for 7 weeks
Study NCT00741884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID for 7 weeks
Study NCT00003256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Study NCT02226276 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo fludeoxyglucose F 18 PET/CT
Study NCT02226276 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo fludeoxyglucose F 18 PET/CT
Study NCT02226276 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo fludeoxyglucose F 18 PET/CT
Study NCT02226276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT02226276 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: copper Cu 64-DOTA-trastuzumab
Description: Given IV
Study NCT02521922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VSP System - NEHB Configuration
Description: VSP System - NEHB Configuration will take and record participant vital signs. NEHB is the last name of the physician who developed the configuration. It is not an acronym.
Study NCT02521922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VSP System - PAL Configuration
Description: VSP System - PAL Configuration will take and record patient vital signs. PAL is the name created by the engineering team of this device. It is not an acronym.
Study NCT03674632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation meditation tape
Description: The tape used in this study is based on a meditation CD designed for breastfeeding mother (Menelli, 2004). The recording will be transcribed and translated into Chinese language by a certified yoga therapist.
Study NCT01180686 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activator IV single impulse instrument
Description: This is a manually operated device that delivers a single thrust into the joint involved.
Study NCT01180686 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multiple thrust Impulse adjusting instrument
Description: A device used for delivering 12 thrusts to the involved joint of the lumbar spine.
Study NCT03796117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed current
Description: For stage 1 of the study, which corresponds to analysis of the evoked torque, evaluation of the discomfort level, current intensity, analysis of neuromuscular efficiency and clinical efficiency, 2 configurations (PC1 and PC2) will be used.~PC1, will be set at a frequency of 100 Hz, phase duration of 1000 microseconds, ON-OFF time of 5s:10s.~PC2, will be set at a frequency of 100 Hz, phase duration of 200 microseconds ON-OFF time of 5s:10s.~For stage 2 of the study, which corresponds to the analysis of the fatigability level, only the PC1 configuration will be used.
Study NCT03796117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Russian Current
Description: For stage 1 of the study, which corresponds to analysis of the evoked torque, discomfort level, current intensity, neuromuscular efficiency and clinical efficiency, 2 configurations (RC1 and RC2) will be used.~RC1, will be set to a frequency of 100 Hz, burst duty cycle of 20%, ON-OFF time of 5s:10s.~RC2, will be set at a frequency of 100 Hz, burst duty cycle of 50%, ON-OFF time of 5s:10s.~For stage 2 of the study, which corresponds to the analysis of the fatigability level, only the RC2 configuration will be used.
Study NCT04327570 — intervention group
Intervention type: OTHER
Intervention: Patient sampling
Description: Blood draw, NP/rectal swab, bronchoscopy if clinically indicated, lung tissue if applicable
Study NCT02226276 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo copper Cu-DOTA-trastuzumab PET
Study NCT02226276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ado-trastuzumab emtansine
Description: Given IV
Study NCT02226276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01813760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Illuiminage ® Diode Laser
Description: Diode laser for treatment of peri-orbital and peri-oral wrinkles
Study NCT04167774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab will be administered as a 30-minute IV infusion Q3W at a dose of 200mg (3mg/kg for underweight patients).
Study NCT02951143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECTRUM cigarettes
Description: Across six laboratory sessions, participants will consume 10 puffs of either their usual brand of cigarette (one session) or a SPECTRUM cigarette (five sessions) with a nicotine yield varying from 0.03 to 0.70 and either menthol (TPMF codes NRC 103, NRC 201, NRC 301, NRC 401, and NRC 601) or tobacco (TPMF codes NRC 102, NRC 200, NRC 300, NRC 400, and NRC 600) flavor, depending on preference. This will be followed by the collection of blood nicotine content and a cigarette purchase task.
Study NCT02951143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECTRUM cigarettes between
Description: Participants will be assigned one of the nicotine concentrations of a SPECTRUM cigarette. They will complete a cigarette purchase task and make real purchases for the next week. Participants will return and make purchases again, repeating 4 times.
Study NCT02220829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preventive administration of Rapaflo
Description: Rapaflo treatment: 8 mg daily during 4 months and 8 mg every other day for 2 months.
Study NCT02220829 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard Care
Description: Administration of alpha-blocker Rapaflo only at onset of symptoms.
Study NCT03575728 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MyChart-MHT
Description: All participants in this study will receive targeted psycho-educational interventions from time to time based on symptom severity reports as determined by the software algorithm
Study NCT00994526 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ham
Description: Ham : 180 g per day during 4 days
Study NCT00994526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ham + calcium
Description: Ham : 160g/d during 4 days calcium : 1000mg/d during 4 days
Study NCT00994526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ham + vitamin E
Description: Ham : 160g/d during 4 days Vitamin E : 80 mg/d during 4 days
Study NCT04382885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Oral Solution
Study NCT04167774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nb-Paclitaxel
Description: nb-Paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 260mg/m2 for 4-6 cycles.
Study NCT00634348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Oral aripiprazole capsules 15 mg once daily from Days 1-14; thereafter, doses could be adjusted on Days 14 and 21 to 10, 15, or 30 mg once daily; patients treated for 28 days
Study NCT03565536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar
Description: for Unresectable tumors ,After the patient had diagnosed as anaplastic thyroid cancer, Nexavar 400mg Bid was used for neoadjuvant treatment. At 1 month and 2 months after treatment, it was assessed whether surgery could be performed.
Study NCT03565536 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: operation
Description: If computed tomography (CT) evaluates for possible surgical treatment, complete thyroidectomy and cervical lymph node dissection are performed to completely resect thyroid tissue and metastatic lymphatic tissue.
Study NCT03565536 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External radiation therapy
Description: As the successful surgery, then continue on the basis of taking on Nexavar plus external beam radiation therapy
Study NCT01068574 — intervention group
Intervention type: OTHER
Intervention: BASIC Score (Observational)
Description: The BASIC Score will be assessed by a study staff, but there are no interventions.
Study NCT03822767 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV-sIPV-bOPV vaccination schedule
Description: Two intramuscular injections of the investigational vaccine (0.5 ml) on Day 0 and Day 30 respectively; Single dose of bOPV (0.1 ml) on Day 60. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by Sinovac Biotech Co., Ltd . The poliovirus (Live) vaccine type I \& type III (Human Diploid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
Study NCT03822767 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: wIPV-wIPV-bOPV vaccination schedule
Description: Two intramuscular injections of the control vaccine(0.5 ml) on Day 0 and Day 30 respectively; Single dose of bOPV (0.1 ml) on Day 60. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by SANOFI PASTEUR S.A. The poliovirus (Live) vaccine type I \& type III (Human Diploid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
Study NCT02701153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgery
Study NCT02701153 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy
Study NCT02701153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02701153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04206488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093
Description: Participants will receive JNJ-70033093 orally.